DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was ...

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

Medical device company DexCom (NASDAQ:DXCM) in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

This article is... The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit. Ken Griffin, the founder of ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...

DXCM’s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DXCM made continued advancements concerning key strategic objectives and ended the quarter with new patient additions.

The following seven stocks are all "strong buys" at five or more Wall Street firms, and have zero sell ratings at present.